MyFibroScan 2.3.0

FibroScan® offers a non-invasive solution for the comprehensive management of liver health. It provides unique and patented biomarkers, including Liver Stiffness Measurement (LSM by VCTE™) and Controlled Attenuation Parameter (CAP™). These biomarkers have a strong foundation in global clinical evidence with over 2500 peer-reviewed publications and endorsements in more than 60 international guidelines.

The myFibroScan app serves as a valuable companion to FibroScan®, facilitating easy, fast, and intuitive access to the Interpretation Guide and FibroScan® based scores:

• The Interpretation Guide leverages data from clinical studies to aid healthcare providers in interpreting FibroScan® examination results.
• Scores enhance the assessment of liver disease using FibroScan® by incorporating biological markers.
• These scores are educational services intended for licensed healthcare professionals. Although informative on specific medical issues, they do not replace personalized medical advice and should not be relied upon as the sole basis for individualized medical decisions.

Specifically tailored aids offered by FibroScan® include:

• Agile™3+, designed to assist in identifying non-alcoholic fatty liver disease (NAFLD) patients with advanced fibrosis through the integration of VCTE™ and routine clinical parameters, diminishing the necessity for liver biopsy. Noteworthy clinical performance is evident in extensive external validation cohorts from various geographic regions.
• Agile™4, aimed at early identification of NAFLD patients with cirrhosis by combining VCTE™ and routine clinical parameters. This tool aids physicians in disease management to mitigate liver-related complications like hepatocellular carcinoma. Superior clinical efficacy is validated across large external validation cohorts originating from diverse locations.
• Fast™, a valuable tool for identifying at-risk patients with non-alcoholic steatohepatitis (NASH) defined as NASH + NAS≥4 + F≥2. The tool showcases good to excellent performance across varied clinical setups (NAFLD tertiary care unit, screening practices, bariatric surgery) and geographic regions (USA, Europe, Asia). Multiple publications advocate for the use of Fast™ due to its robust efficacy.